SCHEMBL5365765

SCHEMBL5365765

CNS(=O)(=O)c1ccc2c(c1)C(=Cc1cc(Cl)ccc1O)C(=O)N2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 3/20 0.52
NTRK1 P04629 2/20 0.52
FCER2 P06734 1/20 0.52
SYK P43405 1/20 0.52
NTRK3 Q16288 1/20 0.52
NTRK2 Q16620 1/20 0.52
CDK2 P24941 2/20 0.51
LRRK2 Q5S007 6/20 0.50
KDR P35968 2/20 0.49
PSEN1 P49768 2/20 0.49
PSEN2 P49810 2/20 0.49
APH1B Q8WW43 2/20 0.49
NCSTN Q92542 2/20 0.49
APH1A Q96BI3 2/20 0.49
PSENEN Q9NZ42 2/20 0.49
PDGFRB P09619 2/20 0.47
EGFR P00533 1/20 0.47
ERBB2 P04626 1/20 0.47
LCK P06239 1/20 0.47
FYN P06241 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5369883 0.89 NTRK1 (0.55) SRCNTRK1FCER2SYKNTRK3
SCHEMBL5366300 0.87 SRC (0.52) SRCNTRK1FCER2SYKNTRK3
SCHEMBL5365553 0.87 PLK4 (0.53) SRCNTRK1FCER2SYKNTRK3
SCHEMBL7139608 0.87 SRC (0.54) SRCNTRK1FCER2SYKNTRK3
SCHEMBL5365279 0.85 SYK (0.68) SRCNTRK1FCER2SYKNTRK3
SCHEMBL5368728 0.85 LRRK2 (0.53) SRCNTRK1FCER2SYKNTRK3
SCHEMBL5360933 0.85 MAP3K7 (0.58) SRCNTRK1FCER2SYKNTRK3
SCHEMBL5363782 0.85 NOX4 (0.57) SRCNTRK1FCER2SYKNTRK3
SCHEMBL7136913 0.83 LRRK2 (0.57) SRCNTRK1FCER2SYKNTRK3
SCHEMBL7137047 0.83 SRC (0.52) SRCNTRK1FCER2SYKNTRK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed
US-6506763-B2 Useful in prevention and treatment of protein kinase related disorders such as cancer SUGEN, INC. 2003-01-14 US disclosed
EP-0984930-A1 2-INDOLINONE DERIVATIVES AS MODULATORS OF PROTEIN KINASE ACTIVITY Sugen, Inc. (US) 2000-03-15 EP disclosed
WO-1998050356-A1 2-INDOLINONE DERIVATIVES AS MODULATORS OF PROTEIN KINASE ACTIVITY SUGEN, INC. (US) 1998-11-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK SRC 189/4885NTRK1 223/4885FCER2 1878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.